At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed NSCLC
- ✓Stage IIIB/IV with progressive disease after first-line platinum-based chemotherapy (taxanes, gemcitabine, or vinorelbine)
- ✓At least one measurable lesion by modified WHO criteria
- ✓EGFR expression assessment available via archived tissue or cytology
- ✕Prior EGFR-directed therapy or EGFR signal transduction inhibitors
- ✕Prior treatment with pemetrexed
- ✕Radiotherapy or major surgery within 30 days
- ✕Documented or symptomatic brain metastases or leptomeningeal disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
In Brief
A Phase 2 clinical trial evaluating Pemetrexed and Matuzumab for Lung Cancer and Non Small Cell Lung Carcinoma. Completed, enrolled 150 participants across 58 sites in 3 countries.
Detailed Summary
This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung cancer by combining matuzumab, a monoclonal antibody, with a chemotherapy treatment, called pemetrexed.
Study Details
Timeline
Interventions
Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.